According to a press release issued earlier this month the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for a generic version of Zytiga (abiraterone acetate) named Yonsa.
The drug, if approved will be manufactured by Churchhill Pharmaceuticals, is called Yonsa. This version of Zytiga is different from the original; it is described, by Churchill as a ultra-micro sized tablet.
Studies have shown that the new formulation used in Yonsa doubles the bioavailability of the drug. His means that only one-half the number of this much smaller pill would need to be taken compared to the current formulation of Zytiga. Many men complain that the current formulation of Zytiga is too difficult to swallow because of its large pill size and the number of pills that are required.
The FDA has until March 19, 2018, to review the NDA application.
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with 5 primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma and a rare cancer, Appendiceal Cancer.
